- Home
- INCY vs FFIV Comparison
INCY vs FFIV Comparison
Compare INCY & FFIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INCY | FFIV |
|---|---|---|
| Founded | 1991 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Computer Communications Equipment |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0B | 14.9B |
| IPO Year | 1994 | 1999 |
Fundamental Metrics
Financial Performance| Metric | INCY | FFIV |
|---|---|---|
| Price | $100.35 | $270.09 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 21 | 10 |
| Target Price | $100.63 | ★ $305.50 |
| AVG Volume (30 Days) | ★ 1.7M | 851.4K |
| Earning Date | 05-12-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 4173.33 | 23.56 |
| EPS | ★ 6.41 | 3.10 |
| Revenue | ★ $3,394,635,000.00 | $3,088,072,000.00 |
| Revenue This Year | $11.02 | $8.00 |
| Revenue Next Year | $9.97 | $3.27 |
| P/E Ratio | ★ $15.81 | $89.80 |
| Revenue Growth | ★ 13.67 | 9.66 |
| 52 Week Low | $53.56 | $223.76 |
| 52 Week High | $112.29 | $346.00 |
Technical Indicators
Market Signals| Indicator | INCY | FFIV |
|---|---|---|
| Relative Strength Index (RSI) | 45.79 | 47.97 |
| Support Level | $97.99 | $255.77 |
| Resistance Level | $109.49 | $270.70 |
| Average True Range (ATR) | 3.58 | 8.86 |
| MACD | -0.26 | -0.82 |
| Stochastic Oscillator | 24.61 | 39.64 |
Price Performance
Historical ComparisonAbout INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About FFIV F5 Inc.
F5 is a market leader in the application delivery controller market. The company sells products for security, application performance, and automation. Its three customer verticals are enterprises, service providers, and government entities. Revenue is evenly split between its services business and products business with revenue trending toward products due to software adoption. The Seattle-based firm was incorporated in 1996, and went public in 1999.